Effects of Miglitol on Caloric Efficiency and Lipid Profiles in Obese Male SHR/Ntul//-cp Rats
DOI:
https://doi.org/10.14738/bjhmr.116.17854Keywords:
Obesity, Diabetes, T2DM, Cholesterol, Lipid Profiles, Sucrase, a-Glucosidase Inhibition, Miglitol, RatsAbstract
Elevations in plasma lipid profiles are a common observation in overweight, obese, hyperinsulinemic, and adult-onset diabetes. The effects of luminal inhibition of starch digestion on parameters of weight gain and plasma lipid profiles were determined in groups of adult obese male T2DM SHR/Ntul//-cp rats. Animals were fed a USDA-formulated, nutritionally complete diet containing 54% sucrose (SUC, CHO) component (Control) or the same diet containing a pharmacologic α-glucosidase inhibitor (1,5 dideoxy-1,5-[(2-hydroxyethyl) imino]-D glucitol; generic miglitol), 150 mg/kg diet, ad libitum for up to 8 weeks. Miglitol resulted in modest decreases in food intake and net weight gain. At the end of the study. heparinized bloods were collected for determination of plasma cholesterol, low-density lipoprotein (LDL) and high density lipoprotein (HDL) fractions. The miglitol-associated luminal inhibition of glucosidase activity resulted in 20% reduction in total cholesterol, and in both α- (LDL) and β-lipoprotein (HDL) fractions. These results indicate that simple inhibition of luminal α-glucosidase activity via miglitol may be a useful adjunct in the clinical management of hypercholesterolemia in states of obesity, T2DM and other glucose intolerant states, in addition to therapeutic applications in enhancing and improving glycemic control in man and animals.
References
Kelly, T, Yang, CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 32(9):1431-1437. 2008.
Wiley, CD, Campisi, J. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nat Metab. 2021 Oct;3(10):1290-1301. PMID: 34663974 PMCID: PMC8889622 DOI: 10.1038/s42255-021-00483-8
Njoloma, I, Lewis, N, Sainvil, F, et al. A primer on hypertension and the racial / ethnic disparities in diagnosis and management. A comprehensive overview. Int J Family & Clin Med 2021;5(6):229-239.
Anderson, M.E, and Tulp, O.L. The Effects of High Dietary Fructose Consumption on the Development of Gout. MOJPH 2023:4(1). 1019 PP1-9. ,
Assefa, ST Yang, E-Y, Chae, S-Y, Song, M, et al. Alpha Glucosidase Inhibitory Activities of Plants with Focus on Common Vegetables. Plants (Basel). 2020 Jan; 9(1): 2-19. Published online 2019 Dec 18. Doi: 10.3390/plants9010002 PMCID: PMC7020213. PMID: 31861279
DeBouno, O.E. Michaelis IV, and O.L. Tulp, “The effects of the intestinal glucosidase inhibitor Bay M 1099 (Miglitol) on glycemic status of obese rats”, Nutrition Research, 9 1041 -1052, 1989.
Tulp OL. Effect of delayed luminal carbohydrate uptake via α-glucosidase inhibition on plasma glycemic parameters and lipid profiles in adult wistar fatty rats. Gastroenterol Hepatol Open Access 2022;13(5):168–173. DOI: 10.15406/ghoa.2022.13.00518
Greenhouse, DD. New Models of genetically obese rats for studies of diabetes, heart disease, and complications of obesity. ILAR J 1990;32(3):1-3.
Tulp, OL. Characteristics of thermogenesis, obesity, and longevity in the LA/Ntul// –cp rat. ILAR J. 32(3), Tulp, O. L. (2024). Effects of Miglitol on Caloric Efficiency and Lipid Profiles in Obese Male SHR/Ntul//-cp Rats. British Journal of Healthcare and
Michaelis, OE IV, Ellwood, KC, Tulp, OL et al. Effect of feeding sucrose or starch diets on parameters of glucose tolerance. Nutrition Research 1986:6(1): 95-99.
Hansen, C.T. The development of the SHR/N and LA/N-cp rat strains. In: Ner models of genetically obese rats for studies in diabetes, heart disease, and complications of obesity. NIH publication, Division of Research Services, Veterinary Resources Branch, NIH, Bethesda MD USA 1988, pp7-10.
Bucolo G and David H. Determination of cholesterol lipoproteins via affinity chromatography. Clin Chem 4:476-481. 1973.
Biostat ref Nie, N., Hull, C.H., Jenkins, K., Sternbrunner, K and Bent, D. Statistical Package for the Social Sciences, 2nd Ed., NY: McGraw Hill.
Page, E.B. Ordered Hypothesis for Multiple Treatments: A significance Test for Linear Ranks. K Amer Stat Assn; 1963:58(301), 216-230.
Jing Ai, Ning Wang, Mei Yang, Zhi-Min Du, Yong-Chun Zhang, and Bao-Feng Yang. Development of Wistar rat model of insulin resistance. Wistar rat historical record World J Gastroenterol. 2005 Jun 28; 11(24): 3675–3679. Published online 2005 Jun 28. Doi: 10.3748/wjg. v11.i24.3675. PMID: 15968719. PMCID: PMC4316015
Ikeda, H. and Matsuo, T. (1981) A new genetically obese hyperglycemic rat (Wistar fatty). Diabetes, 30, 1045-1050. doi:10.2337/diabetes.30.12.1045
Zucker, LM and Zucker, TF. Fatty, a new mutation in the rat. Journal of Heredity, Volume 52, Issue 6, November-December 1961, Pages 275–278, https://doi.org/10.1093/oxfordjournals.jhered.a107093
Peterson, RG., Little, LA, and Neel, M-A. WKY Fatty Rat as a Model of Obesity and Non-insulin-dependent Diabetes Mellitus. ILAR Journal, Volume 32, Issue 3, 1990, Pages 13–15. https://doi.org/10.1093/ilar.32.3.13
O.L. Tulp, C. Stevens, O. Barbie, and O.E. Michaelis IV, Comparative Effects of Acarbose on Glycemia, Weight Gain, and Serum Lipids in Adult Male and Female Diabetic Wistar Fatty Rats. Proceedings of Second International Symposium on Acarbose, Nov. 1987.
Boque, N., Campion, J., Paterman, L., Garcia-Diaz, D.F., Galarraga, M., Portillo, MP et al. Influence of dietary macronutrient composition on adiposity and cellularity of different fat depots in Wistar rats. J. Physiol Biochem 2009; 65(4):387-395.
Vedula U, Schnitzer-Polokoff, R, and Tulp, O. The effect of acarbose on the food intake, weight gain, and adiposity in LA/Ntul//-cp rats. Comp Biochem Physiol A> 1991:100:477-482. 1991.
Riccardi G, Giacco R, Parillo M, Turco S, Rivellese AA, Ventura MR, Contadini S, Marra G, Monteduro M, Santeusanio F, Brunetti P, Librenti MC, Pontiroli AE, Vedani P, Pozza G, Bergamini L, Bianchi C. Efficacy, and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med. 1999 Mar;16(3):228-32.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M., STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 Jun 15;359(9323):20727
Ziaee A, Esmailzadehha N, Honardoost M. Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus. Pak J Med Sci. 2017 May-Jun;33(3):686-690.
Mughal, MA, Memon, MY,, Zardari, MK, Tanwani, RK, and Ali, M. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes. J Pak Med Assoc. 2000 May;50(5):152-6. PMID:
Leonhardt W, Hanefeld M, Fischer S, Schulze J. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidemia. Eur J Clin Invest. 1994 Aug;24 Suppl 3:45-9. Doi: 10.1111/j.1365-2362. 1994.tb02256. x. PMID: 8001628 Review.
Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther. 2012 Sep;29(9):736-46. Doi: 10.1007/s12325-012-0045-5. Epub 2012 Aug 24. PMID: 22923161 Review.
Leonhardt, W, Hanefeld, M, Fischer, S, Schulze, J, and Spengler, M.. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment Arzneimittelforschung. 1991 Jul;41(7):735-8. PMID: 1772463
Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K.Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 1991 Aug;14(8):732-7. Doi: 10.2337/diacare.14.8.732. PMID: 1954810 Clinical Trial.
Hoffmann J, Spengler M Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietarytreated NIDDM patients: the Essen-II Study. . Am J Med. 1997 Dec;103(6):483-90. Doi: 10.1016/s0002-9343(97)00252-0. PMID: 9428831 Clinical Trial.
Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebocontrolled dose-comparison study. Diabetes Care. 1995 Jun;18(6):817-24. Doi: 10.2337/diacare.18.6.817. PMID: 7555508 1,2, 2 2
Satoru Sugimoto Hisakazu Nakajima , Kitaro Kosaka , Hajime Hosoi. Review: Miglitol has potential as a therapeutic drug against obesity. Nutr Metab (Lond) 2015 Dec 1; 12:51. doi: 10.1186/s12986-015-0048-8 PMCID: PMC4666030 PMID: 26628904
L J Scott 1, C M Spencer. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus
Drugs. 2000 Mar;59(3):521-49. doi: 10.2165/00003495-200059030-00012
Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care. 1997 May;20(5):687-91. doi: 10.2337/diacare.20.5.687. PMID: 9135927
Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM. Long-term titrated-dose alphaglucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care. 1998 Mar;21(3):409-15. doi: 10.2337/diacare.21.3.409. PMID: 9540024
Chiasson, J-L., Naditch, L. The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes. Diabetes Care: Clinical Education / Nutrition| June 01 2001 l Care /Education / Nutrition| June 01 2001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Orien L Tulp
This work is licensed under a Creative Commons Attribution 4.0 International License.
